Table 3.

EORs and 95% CIs for I-131 Thyroid Dose by Nodule Grouping in the Ukraine In Utero Cohort: Second Thyroid Screening, 2012–2015

	All Subjects						Subjects With Postnatal I-131 Thyroid Dose <0.30 mGya
Nodule Grouping				Dose Term						Dose Term
	n	EORb per Gy	P Linearc	Lineard	Exponentiale	P Expf	n	EOR per Gy	P Linear	Linear	Exponential	P Exp
Any nodule	241	1.53	0.015	4.92	–1.55	0.038	229	2.01	0.004	3.38	–0.77	0.296
		0.22, 3.59g		1.13, 12.36	–3.98, –0.08			0.49, 4.41		0.64, 9.16	–2.90, 0.67
Benign nodule	221	1.19	0.075	5.48	–1.98	0.021	211	1.71	0.023	3.98	–1.28	0.141
		–0.09, 3.25		1.08, 14.20	–5.12, –0.30			0.18, 4.15		0.61, 11.24	–4.32, 0.41
<10 mm	178	0.34	0.604	6.20	–3.16	0.039	171	0.79	0.307	4.33	–2.34	0.131
		–0.67, 2.24		–28.05, 28.17	–22.86, –0.22			–0.52, 3.15		–12.86, 34.59	NE, 1.07
≥10 mm	43	4.19	0.009	7.34	–0.83	0.324	40	5.04	0.005	5.82	–0.24	0.781
		0.68, 11.62		<–2.44, 25.54	–3.12, 0.79			0.98, 13.73		0.75, 20.72	–2.44, 1.37

Abbreviations: exp, exponential; NE, not estimable.

^aAnalyses are based on cumulative I-131 thyroid dose (prenatal plus any postnatal component) for all subjects and then restricted to subjects with postnatal I-131 dose <30 mGy.

^bEOR per Gy is estimated from simple linear model and adjusted for sex.

^cOne degrees of freedom test for linear trend.

^dLinear dose term from linear-exponential model adjusted for sex.

^eExponential dose term from linear exponential model adjusted for sex.

^fOne degrees of freedom test for exponential departure from linearity.

^g95% CI.